← All trials
NCT07277231
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2026
- Primary completion
- Feb 28, 2031
- Completion date
- Nov 30, 2031
- First posted
- Dec 11, 2025
- Last posted
- Dec 11, 2025
- Enrollment
- 500
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- BeOne MedicinesLead sponsor
- BeOne MedicinesOfficial
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.